Navigation Links
EUSA Pharma Completes Acquisition Of Cytogen Corporation
Date:5/9/2008

specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has nine products on the market, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint(R) for imaging the extent and spread of prostate cancer, Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, the antibiotic surgical implant Collatamp(R) G, and Rapydan(R), a rapid-onset anesthetic patch which recently received Europe-wide approval. EUSA also has several products in late-stage development, notably Collatamp(R) G topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx(R) bupivacaine implant* for local post-surgical pain control.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of t
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014 Continental Clinical ... populations into clinical trials at its mid-Atlantic late-phase ... “Continental was created with the idea of closing ... fundamental role in medical advances," said Continental's CEO, ... experiment to the immortal cell line of Henrietta ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
(Date:11/22/2014)... 2014 CannLabs, Inc. (OTCQB: ... and scientific testing methodologies relating to cannabis, today announced ... line of credit from an existing stockholder of the ... secured this commitment from one of our existing stockholders,” ... “This capital will help accelerate our planned expansions into ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2
... (NASDAQ: NBIX ) announced today that it ... initial cohort of Tardive Dyskinesia patients using its proprietary ... this data, the Company is initiating the Investigational New ... Drug Administration (FDA). "We are very pleased ...
... announces that a new market research report is ... Sequencing - technologies, markets and companies ... report briefly reviews basics of human genome variations, ... large and small sequencers are described as well ...
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for drug discovery and life-sciences research, today announced that ... formed a research collaboration with Denver-based Catholic Health Initiatives ... The health care system,s Center for Translational Research ...
Cached Biology Technology:Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 2Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 3Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 4Reportlinker Adds DNA Sequencing - Technologies, Markets and Companies 2Caliper Announces New Oncology Research Collaboration 2Caliper Announces New Oncology Research Collaboration 3
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/6/2014)... team of Florida State University biologists could lead to ... and survive environmental swings such as droughts or floods. ... the journal The Plant Cell , sheds light ... is organized in a cell and how plants regulate ... and others are turned off. , "If you understand ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2
... FL, January 30, 2014 Scientists from the Florida ... awarded approximately $1.8 million from the National Cancer Institute ... signaling pathways that underlie lung cancer and to use ... Kissil, a TSRI associate professor, will be principal investigator ...
... say they have opened the window on the natural process of ... could be used to advance therapies for bone fractures and disease. ... the Feb. 13 issue of the journal Cell Reports , ... to allow adult zebra fish to perfectly replace bones lost upon ...
... in German . ... neurons in the brain. Nerve growth factors produced by the body, ... tests with GDNF have not yielded in any clear improvements. Scientists ... colleagues have now succeeded in demonstrating that GDNF and its receptor ...
Cached Biology News:Zebra fish fins help Oregon researchers gain insight into bone regeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3